Suchen
Edwards Lifesciences Corp
EWZur Watchlist hinzufügen
87.360USD
+0.680+0.78%
Handelsschluss 06/18, 16:00（ET）Kurse um 15 Minuten verzögert
50.30BMarktkapitalisierung
46.39KGV TTM
mehr Informationen über Edwards Lifesciences Corp Unternehmen
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp Informationen
BörsenkürzelEW
Name des UnternehmensEdwards Lifesciences Corp
IPO-datumMar 27, 2000
CEOZovighian (Bernard J)
Anzahl der mitarbeiter15800
WertpapierartOrdinary Share
GeschäftsjahresendeMar 27
AddresseOne Edwards Way
StadtIRVINE
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl92614
Telefon19492502500
Websitehttps://www.edwards.com
BörsenkürzelEW
IPO-datumMar 27, 2000
CEOZovighian (Bernard J)
Führungskräfte von Edwards Lifesciences Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Edwards Lifesciences Corp?
Die fünf größten Anteilseigner von Edwards Lifesciences Corp sind: Mr. Scott B. Ullem
Wie viele Institutionen halten Anteile an Edwards Lifesciences Corp (EW)?
Mit Stand vom 2026Q1 halten 2620 Institutionen Anteile an Edwards Lifesciences Corp, mit einem Gesamtmarktwert von etwa 539.60M, was 93.71% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -12944884.00 gestiegen.
Was ist die größte Einnahmequelle von Edwards Lifesciences Corp?
Am 2026Q1 erzielte das Geschäft mit Transcatheter Aortic Valve Replacement für Edwards Lifesciences Corp den höchsten Umsatz in Höhe von 4.49B, was 73.96% des Gesamtumsatzes entspricht.
